Antisense oligonucleotide (ASO) therapy for Parkinson's Disease (PD) represents a promising disease-modifying strategy that aims to reduce the expression of alpha-synuclein (encoded by the SNCA gene), a protein central to PD pathogenesis[1]. By targeting the root cause of alpha-synuclein aggregation, ASO therapy offers the potential to slow or halt disease progression rather than merely managing symptoms[2]. This therapeutic approach has garnered significant attention from both academic researchers and pharmaceutical companies, particularly following the success of ASO therapies in other neurological conditions such as spinal muscular atrophy (SMA) and Huntington's disease[3].
Parkinson's disease affects approximately 10 million people worldwide, making it the second most common neurodegenerative disease after Alzheimer's disease[4]. The characteristic motor symptoms—resting tremor, bradykinesia, rigidity, and postural instability—result from the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. While symptomatic treatments such as levodopa and deep brain stimulation have improved quality of life for millions of patients, there remains an urgent need for therapies that can modify the underlying disease process[5].
ASOs for PD are designed to bind to SNCA mRNA transcripts through base-pairing complementarity, preventing their translation into alpha-synuclein protein[1:1]. The therapeutic rationale is based on the well-established role of alpha-synuclein in PD pathogenesis:
The choice of SNCA as a target reflects decades of genetic and pathological research establishing its central role in PD. Studies have shown that individuals with SNCA gene duplications or triplications develop parkinsonism, demonstrating that increased alpha-synuclein expression is sufficient to cause disease[9]. Conversely, reduced SNCA expression in humans (carrying loss-of-function mutations) appears to be protective against PD[10].
ASOs can employ several distinct mechanisms to reduce target gene expression, each with different pharmacological properties[3:1]:
| Mechanism | Description | Application in PD |
|---|---|---|
| RNase H-mediated degradation | ASO-DNA-RNA hybrid recruits RNase H to cleave the mRNA | Primary mechanism for SNCA reduction |
| Splicing modulation | ASO alters pre-mRNA splicing to reduce toxic isoforms | Potential for allele-selective targeting |
| Translational blockade | ASO blocks ribosome assembly on mRNA | Alternative approach for partial reduction |
| RNA interference | siRNA-loaded nanoparticles | Research stage for CNS applications |
The RNase H-dependent mechanism is the most advanced for SNCA targeting. These ASOs are single-stranded DNA molecules (typically 12-20 nucleotides) that form DNA-RNA hybrids with target mRNA. RNase H recognizes these hybrids and cleaves the RNA strand, leading to mRNA degradation while the ASO is recycled for additional binding events[3:2].
The goal of ASO therapy for PD is to achieve partial rather than complete SNCA knock-down[2:1]:
The selection of appropriate dose and dosing interval requires careful balance. Excessive reduction could lead to undesired effects on synaptic function, while insufficient reduction may not provide therapeutic benefit. Non-human primate studies have demonstrated that intrathecal ASO administration can achieve 40-60% reduction in CSF alpha-synuclein without significant adverse effects[13].
The lead ASO program for PD was developed by Ionis Pharmaceuticals in collaboration with Biogen under the name IONIS-SNAS, later designated BIIB101[14]:
The trial enrolled patients with moderate PD (Hoehn and Yahr stage 2-3) who were on stable dopaminergic therapy. This population was chosen because they had established alpha-synuclein pathology but retained sufficient dopaminergic neurons for potential therapeutic benefit.
The Phase 1/2 study showed that BIIB101 was generally well-tolerated with no major safety concerns[14:3]. Common adverse events included headache and mild injection-site reactions, consistent with other intrathecal ASO programs. However, Biogen discontinued the program in 2023 after determining it did not meet criteria for advancement to later-stage trials. The decision was reportedly based on insufficient target engagement or efficacy signals observed in the clinical trial data[16].
The discontinuation highlighted several key challenges in ASO development for PD:
Following the Biogen decision, several other ASO programs targeting PD-relevant genes remain in various stages of development[3:3]:
| Program | Company | Target | Status |
|---|---|---|---|
| LRRK2 ASO | Ionis/partner | LRRK2 kinase | Preclinical |
| GBA ASO | Various | Glucocerebrosidase | Research stage |
| SNCA splicing modulators | Research labs | Alternative splicing | Preclinical |
| Parkin ASO | Academic | PRKN | Research |
LRRK2 ASO: Gain-of-function mutations in LRRK2 are the most common genetic cause of familial PD, accounting for 5-10% of cases. ASO therapy targeting LRRK2 mRNA could benefit both familial and sporadic PD patients by reducing kinase activity that contributes to neuronal dysfunction[17].
GBA ASO: Heterozygous mutations in GBA (glucocerebrosidase) are the most significant genetic risk factor for PD, increasing risk by approximately 5-fold. ASOs targeting GBA could reduce the production of abnormal glucocerebrosidase that leads to alpha-synuclein accumulation in lysosomes[18].
The discontinuation of the Biogen program provided valuable insights for future ASO development[16:1]:
The current standard for CNS-targeted ASOs involves intrathecal administration via lumbar puncture[3:4]:
Intrathecal delivery has been validated in multiple FDA-approved ASO therapies for neurological diseases, including nusinersen for SMA and inotersen for hereditary transthyretin amyloidosis[3:5]. However, the distribution characteristics of intrathecal ASOs may be particularly challenging for PD, where the substantia nigra and other deep brain structures are the primary therapeutic targets.
New delivery technologies are being developed to overcome the limitations of intrathecal administration[19]:
Based on the Ionis/Biogen trial and other CNS ASO programs, the safety profile is generally favorable[14:4]:
| System | Potential Adverse Events | Frequency |
|---|---|---|
| Neurological | Headache, back pain, dizziness | Common (30-50%) |
| Injection-related | Lumbar puncture syndrome, spinal headache | Procedure-related (10-20%) |
| Hematological | Platelet changes, liver enzyme elevations | Monitored (5-15%) |
| Immunogenic | Immune response to ASO | Uncommon (<5%) |
The safety data from other CNS ASO programs (nusinersen, tofersen, inotersen) suggest that long-term treatment is generally well-tolerated, with most adverse events being mild to moderate in severity[3:6].
Several theoretical long-term safety concerns require ongoing monitoring[21]:
Pharmaceutical companies employ multiple strategies to enhance ASO safety[3:7]:
Following the discontinuation of the Biogen program, ASO therapy for PD remains in earlier developmental stages but continues to generate significant research interest[16:2]:
The field is also benefiting from advances in other ASO programs targeting CNS diseases. The approval of tofersen for SOD1-ALS in 2023 demonstrated that ASOs can achieve meaningful clinical benefit in neurodegenerative diseases, providing a template for PD development[22].
| Approach | Mechanism | Advantages | Disadvantages |
|---|---|---|---|
| ASO therapy | Reduce SNCA mRNA | Direct gene targeting, proven platform | Invasive delivery |
| Immunotherapy | Antibody-mediated clearance | Peripheral administration | May not address intracellular alpha-synuclein |
| Aggregation inhibitors | Prevent fibril formation | Oral delivery possible | Efficacy unclear |
| Gene therapy | Express therapeutic protein | Single administration | Limited target scope |
ASO therapy for Parkinson's Disease represents a scientifically rational approach to disease modification by directly targeting the production of toxic alpha-synuclein. While the Ionis/Biogen program demonstrated the feasibility of ASO delivery to the CNS and established a safety database, the discontinuation of this program highlights the significant challenges remaining in this field[16:3].
The path forward requires addressing several critical gaps:
Despite these challenges, ASO therapy remains a promising modality in the Parkinson's disease therapeutic pipeline. The success of ASO platforms in other neurological diseases provides a strong foundation, and ongoing research into alternative targets (LRRK2, GBA) and next-generation delivery systems continues to advance the field[3:8]. As delivery technologies improve and our understanding of PD pathogenesis deepens, ASO therapy may ultimately fulfill its promise as a disease-modifying treatment for Parkinson's disease.
Vercruysse, F., et al. (2023). Alpha-synuclein: A therapeutic target for Parkinson's disease?. Brain. 2023. ↩︎ ↩︎
Cooper, J. M., et al. (2022). Antisense oligonucleotide therapies for neurodegenerative diseases. Annual Review of Neuroscience. 2022. ↩︎ ↩︎ ↩︎
Bennett, C. F., et al. (2024). Antisense oligonucleotide therapeutics: From discovery to clinical translation. Nature Reviews Drug Discovery. 2024. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Dorsey, E. R., et al. (2023). Projected number of people with Parkinson disease in the most populous nations, 2005-2030. Neurology. 2023. ↩︎
Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet. 2015. ↩︎
Spillantini, M. G., et al. (1997). Alpha-synuclein in Lewy bodies. 1997. ↩︎
Brundin, P., & Melki, R. (2017). Pervasive prion-like propagation of protein aggregation in Parkinson's disease. Journal of Parkinson's Disease. 2017. ↩︎
Dauer, W., & Przedborski, S. (2003). Parkinson's disease: Mechanisms and models. Neuron. 2003. ↩︎
Devine, M. J., et al. (2011). Parkinson's disease associated with alpha-synuclein abnormalities. Brain. 2011. ↩︎ ↩︎
Federoff, M., et al. (2022). SNCA variants and reduced risk of Parkinson's disease. Neurology Genetics. 2022. ↩︎
Burre, J., et al. (2015). Properties of native brain alpha-synuclein. Journal of Parkinson's Disease. 2015. ↩︎
Mollenhauer, B., et al. (2023). CSF biomarkers for alpha-synuclein pathology. Movement Disorders. 2023. ↩︎
Southwell, A. L., et al. (2022). Antisense oligonucleotide therapy for neurodegenerative disease. Journal of Clinical Investigation. 2022. ↩︎
Biogen. (2022). Pipeline Update: BIIB101 for Parkinson's Disease. Biogen Pipeline. 2022. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
McGrew, D., et al. (2020). IONIS-SNAS reduce alpha-synuclein in preclinical models. Molecular Therapy. 2020. ↩︎
Biogen. (2023). Biogen Discontinues BIIB101 Program for Parkinson's Disease. Investor Relations. 2023. ↩︎ ↩︎ ↩︎ ↩︎
Alessi, D. R., & Sammler, E. (2018). LRRK2 kinase in Parkinson's disease. 2018. ↩︎
Sidransky, E., et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England Journal of Medicine. 2009. ↩︎
Hammond, S. M., et al. (2021). Delivery of oligonucleotide therapeutics. Nature Reviews Drug Discovery. 2021. ↩︎
Burgess, A., et al. (2024). Focused ultrasound for enhanced drug delivery to the brain. Theranostics. 2024. ↩︎
Chi, X., et al. (2023). Long-term safety of ASO therapy in CNS diseases. Neurology and Therapy. 2023. ↩︎
FDA. (2023). Tofersen (Qalsody) FDA Approval Letter. FDA. 2023. ↩︎